Sarepta Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SRPT | DSGN | CAPR | IONS | TSHA | STOK | |
|---|---|---|---|---|---|---|
| Market cap | 1.84B | 682.77M | 434.30M | 7.26B | 1.35B | 1.56B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 7.3 | -6.7 | -5.1 | -39.3 | -9.0 | -6.8 |
| Price/book | 1.2 | 3.4 | 1.8 | 16.4 | 5.6 | 4.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −18.72% | +79.51% | +11.49% | −35.85% | −11.09% | −18.46% |
| Today | −2.30% | −6.35% | −4.60% | −3.56% | −7.80% | −2.38% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SRPT news ›Bank of America Securities Reaffirms Their Sell Rating on Sarepta Therapeutics (SRPT)
Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on Sarepta Therapeutics today and set a price target of $18.00. Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Ultragenyx Pharmaceutical,…
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT), Addus Homecare (ADUS) and Perspective Therapeutics (CATX). In a report released today, Anupam Rama from J.P.…
Gene Therapy Patent Suit Against Sarepta Comes To Close
By Adam Lidgett · October 9, 2026, 8:03 PM EDT REGENXBIO Inc. et al v. Sarepta Therapeutics, Inc., et al. REGENXBIO Inc. v. Sarepta Therapeutics, Inc. Appellate - Federal Circuit 830 Patent Infringement (Fed. Qst.)
Silence Therapeutics plc: News in other languages | SLN | US82686Q1013
Silence Therapeutics plc: News, information and stories for Silence Therapeutics plc | Nasdaq: SLN | Nasdaq Other languages Silence Therapeutics plc Biotechnology & Medical Research All financial news and data tailored to specific country…
Kyverna Therapeutics to Present at Upcoming Investor Conferences
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pione... Kyverna Therapeutics to Present at Upcoming Investor Conferences EMERYVILLE, Calif., Sept.…
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright
Posted by Danessa Lincoln on Oct 6th, 2026 Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by equities researchers at HC Wainwright in a report released on Monday, MarketBeat.com reports. They…
Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics
Toward the end of the October 5 lightning round of Mad Money, a caller asked Jim Cramer about Sarepta Therapeutics, Inc. (NASDAQ:SRPT). He replied: This is a very controversial stock… I want everything to work for people who have this and…
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sarepta…
HC Wainwright & Co. reiterates Sell rating on Sarepta Therapeutics, $5 price target
HC Wainwright & Co. reiterated their Sell rating on Sarepta Therapeutics's stock with a price target of $5.00. The price target implies a downside of 71.4% from the Oct 2 close of $17.50. Underperformance of ELEVIDYS: Sarepta Therapeutics…
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
Dude 3D characters X7 business people pushing up Red Graph. Light Blue 3D Grid background. Sarepta Therapeutics could turn things around yet, Jefferies analysts declared after the embattled biotech presented data showing “durable and…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
theglobeandmail.com3
-
themarketsdaily.com3
-
biospace.com2
-
markets.businessinsider.com2
-
news.alphastreet.com2
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.